Literature DB >> 31157080

Physical and chemical stability of ceftaroline in an elastomeric infusion device.

Farah Al Madfai1, Syed Tabish R Zaidi1, Long Chiau Ming1,2, Troy Wanandy3, Rahul P Patel1.   

Abstract

BACKGROUND: Severe infections such as endocarditis and osteomyelitis require long-term treatment with parenteral antibiotics and hence prolonged hospitalisation. Continuous infusion of ceftaroline through elastomeric devices can facilitate early hospital discharge by managing parenteral antibiotics in patient's home. Therefore, the purpose of this study was to investigate the stability of ceftaroline in a commonly used elastomeric device.
METHOD: A total of 24 elastomeric devices were prepared, and six elastomeric devices containing 6mg/mL of ceftaroline (three in each type of diluents) were stored at one of the following conditions: 4°C for 6 days, 25°C for 24hours, 30°C for 24hours or 35°C for 24hours. An aliquot was withdrawn before storage and at different time points. Chemical stability was measured using a stability indicating high-performance liquid chromatography, and physical stability was assessed as change in pH, colour and particle content.
RESULTS: Ceftaroline, when admixed with both diluents, was stable for 144, 24 and 12hours at 4°C, 25°C and 30°C, respectively. At 35°C, ceftaroline admixed with normal saline (NS) and glucose 5% was stable for 12hours and for 6hours, respectively. No evidence of particle formation, colour change or pH change was observed throughout the study period.
CONCLUSIONS: Our findings support 12 or 24hours continuous elastomeric infusion of ceftaroline-NS admixture, and bulk preparation of elastomeric pumps containing ceftaroline solution in advance. This would facilitate early hospital discharge of patients eligible for the elastomeric-based home therapy and avoid the need for patient's caregivers travelling to the hospital on a daily basis.

Entities:  

Keywords:  antibiotics; ceftaroline; continuous infusion; elastomeric devices; multiple bacterial drug resistance; stability

Year:  2017        PMID: 31157080      PMCID: PMC6319413          DOI: 10.1136/ejhpharm-2017-001221

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  15 in total

1.  Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.

Authors:  Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis
Journal:  J Antimicrob Chemother       Date:  2012-02-06       Impact factor: 5.790

2.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

Review 3.  Outpatient parenteral antimicrobial therapy today.

Authors:  Joseph A Paladino; Donald Poretz
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

4.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

5.  Quality-of-life assessment in an outpatient parenteral antibiotic program.

Authors:  Alan F Goodfellow; Amy O Wai; Luciana Frighetto; Carlo A Marra; Barbara M Ferreira; M Lynn Chase; Ruth E Nicol; Carole A Leong; Sally Tomlinson; Peter J Jewesson
Journal:  Ann Pharmacother       Date:  2002-12       Impact factor: 3.154

6.  In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.

Authors:  Louis Saravolatz; Joan Pawlak; Leonard Johnson
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

Review 7.  Limitations of vancomycin in the management of resistant staphylococcal infections.

Authors:  Marin H Kollef
Journal:  Clin Infect Dis       Date:  2007-09-15       Impact factor: 9.079

Review 8.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Authors:  William A Craig
Journal:  Infect Dis Clin North Am       Date:  2003-09       Impact factor: 5.982

9.  Stability of benzylpenicillin during continuous home intravenous therapy.

Authors:  Jane W A Vella-Brincat; Evan J Begg; Kate Gallagher; Carl M J Kirkpatrick; Mei Zhang; Chris Frampton; Stephen T Chambers
Journal:  J Antimicrob Chemother       Date:  2004-03-10       Impact factor: 5.790

10.  Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.

Authors:  Dilip Nathwani; Gavin D Barlow; Katherine Ajdukiewicz; Kirsteen Gray; John Morrison; Ben Clift; Anthony J France; Peter Davey
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790

View more
  2 in total

Review 1.  Stability of Antimicrobials in Elastomeric Pumps: A Systematic Review.

Authors:  Beatriz Fernández-Rubio; Paula Del Valle-Moreno; Laura Herrera-Hidalgo; Alicia Gutiérrez-Valencia; Rafael Luque-Márquez; Luis E López-Cortés; José María Gutiérrez-Urbón; Sonia Luque-Pardos; Aurora Fernández-Polo; María V Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2021-12-30

Review 2.  Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.